Preeclampsia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Kyowa Kirin, Gynuity Health

October 09 23:14 2023
Preeclampsia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Kyowa Kirin, Gynuity Health
DelveInsight’s “Preeclampsia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Preeclampsia, historical and forecasted epidemiology as well as the Preeclampsia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Preeclampsia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Preeclampsia, historical and forecasted epidemiology as well as the Preeclampsia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Preeclampsia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Preeclampsia Market Forecast

 

Some of the key facts of the Preeclampsia Market Report: 

  • The Preeclampsia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Preeclampsia, the second-leading cause of maternal mortality worldwide, affects between 2-8% of pregnancies, according to statistics gathered from the Agency for Healthcare Research and Quality (2019)
  • Preeclampsia developed in 7.5% of participants, of whom 16.1% had early-onset preeclampsia and the rest had late-onset preeclampsia, according to research by Mayrink et al. (2019)
  • According to a study by Schneider et al. (2019), preeclampsia was substantially related with greater maternal age, gestational diabetes, no prior or multiple births, pre-pregnancy obesity, and above-average weight gain during pregnancy. Smoking seemed to have a detrimental correlation
  • Key Preeclampsia Companies: Kyowa Kirin, Gynuity Health, and others
  • Key Preeclampsia Therapies: KW-3357, Antithrombin gamma, Nifedipine, and others
  • The Preeclampsia epidemiology based on gender analyzed that incidence of pre-eclampsia in a study population is highest for mild cases
  • The Preeclampsia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Preeclampsia pipeline products will significantly revolutionize the Preeclampsia market dynamics.

 

Preeclampsia Overview

Pregnant women who experience high blood pressure, protein in their urine, and swelling in their hands, feet, and legs are said to have preeclampsia, also known as toxaemia. Mild to severe variations are possible. Even while it can occur sooner or right after birth, it typically occurs in the later stages of pregnancy.

 

Get a Free sample for the Preeclampsia Market Report 

https://www.delveinsight.com/report-store/preeclampsia-market

 

Preeclampsia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Preeclampsia Epidemiology Segmentation:

The Preeclampsia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Preeclampsia
  • Prevalent Cases of Preeclampsia by severity
  • Gender-specific Prevalence of Preeclampsia
  • Diagnosed Cases of Episodic and Chronic Preeclampsia

 

Download the report to understand which factors are driving Preeclampsia epidemiology trends @ Preeclampsia Epidemiology Forecast

 

Preeclampsia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Preeclampsia market or expected to get launched during the study period. The analysis covers Preeclampsia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Preeclampsia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Preeclampsia Therapies and Key Companies

  • KW-3357: Kyowa Kirin
  • Antithrombin gamma: Kyowa Kirin Co., Ltd
  • Nifedipine: Gynuity Health

 

Discover more about therapies set to grab major Preeclampsia market share @ Preeclampsia Treatment Market

 

Scope of the Preeclampsia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Preeclampsia Companies: Kyowa Kirin, Kyowa Kirin Co., Ltd, Gynuity Health, and others
  • Key Preeclampsia Therapies: KW-3357, Antithrombin gamma, Nifedipine, and others
  • Preeclampsia Therapeutic Assessment: Preeclampsia current marketed and Preeclampsia emerging therapies
  • Preeclampsia Market Dynamics: Preeclampsia market drivers and Preeclampsia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Preeclampsia Unmet Needs, KOL’s views, Analyst’s views, Preeclampsia Market Access and Reimbursement 

 

To know more about Preeclampsia companies working in the treatment market, visit @ Preeclampsia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Preeclampsia Market Report Introduction

2. Executive Summary for Preeclampsia

3. SWOT analysis of Preeclampsia

4. Preeclampsia Patient Share (%) Overview at a Glance

5. Preeclampsia Market Overview at a Glance

6. Preeclampsia Disease Background and Overview

7. Preeclampsia Epidemiology and Patient Population

8. Country-Specific Patient Population of Preeclampsia 

9. Preeclampsia Current Treatment and Medical Practices

10. Preeclampsia Unmet Needs

11. Preeclampsia Emerging Therapies

12. Preeclampsia Market Outlook

13. Country-Wise Preeclampsia Market Analysis (2019–2032)

14. Preeclampsia Market Access and Reimbursement of Therapies

15. Preeclampsia Market Drivers

16. Preeclampsia Market Barriers

17.  Preeclampsia Appendix

18. Preeclampsia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services